News
Sep 14, 2026 8:02 AM Eastern Daylight Time
FALLS CHURCH, Va.--(BUSINESS WIRE)--Retension Pharmaceuticals, Inc. (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, today announced the formation of its Scientific Advisory Board (SAB). The SAB is expected to provide strategic guidance as well as scientific, clinical trial, and therapeutic area expertise as Retension advances RTN-001 in clinical development in the ongoing Phase 2b clinical trial in patients with hypertension.
Distinguished physicians and investigators in hypertension, cardiovascular diseases, nephrology and innovative cardiovascular trials to advise on the clinical development of RTN-001
Retension Pharmaceuticals Announces Formation of Scientific Advisory Board
September 10, 2026 8:00 AM Eastern Daylight Time
Retension Pharmaceuticals Appoints LeAnne Bloedon, M.S., RD, as EVP of Clinical Development and Operations, and Kevin Schutz, PharmD, as VP Regulatory Affairs
Appointments strengthen clinical and regulatory leadership as the Company advances RTN-001 through its Phase 2b trial
FALLS CHURCH, Va.--(BUSINESS WIRE)--Retension Pharmaceuticals, Inc. (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, today announced that LeAnne Bloedon, M.S., RD, and Kevin Schutz, PharmD, have joined the Company as Executive Vice President, Clinical Development and Operations, and as Vice President, Regulatory Affairs, respectively.